
Zytux: A Breakthrough Immunotherapy for Cancer and
2023年2月22日 · Zytux (rituximab) is a monoclonal antibody that is used to treat certain types of cancer and autoimmune diseases, such as non-Hodgkin’s lymphoma, chronic lymphocytic …
A Double-Blind, Randomized Comparison Study between Zytux™ …
2018年4月1日 · Zytux™ (Rituximab, AryoGen Pharmed) is the intended biosimilar product of MabThera ® (Rituximab, Roche) which has exhibited acceptable compatibility profile during …
Zytux in Refractory Myasthenia Gravis: A Multicenter, Open …
2021年8月26日 · Here, we sought to investigate the efficacy and safety of rituximab therapy in the treatment of patients with refractory MG. Methods: In a 48-week, multicenter, open-labeled, …
Rituximab biosimilar (Aryogen)
Zytux™ (Rituximab, AryoGen Pharmed) used in the present study for multiple sclerosis (MS) patients is basically a biosimilar rituximab. In this observational study, a total of 100 patients …
AryoGen Pharmed
Zytux is a biosimilar product with the generic name of Rituximab. It is a genetically engineered human-mouse chimeric monoclonal antibody produced by Chinese Hamster Ovary (CHO) …
Efficacy and safety of biosimilar rituximab (ZytuxTM) in newly ...
2020年12月2日 · Most of treatment protocols of NHL and CLL contain rituximab in addition to chemotherapy, which has been associated with improved survival. The aim of this study was …
Evaluating the efficacy and safety of Zytux - ScienceDirect
2019年11月1日 · Results revealed that the Zytux™ could have a positive effect on MS patients. Anti-CD20 monoclonal antibodies such as ocrelizumab, rituximab, and ofatumumab target B …
Zytux « آریوژن فارمد Aryogen staff are happy with their job …
Zytux™ is supplied as a sterile, clear and colorless concentrate for solution for infusion. It is provided in vials of 10 milliliter and 50 milliliter containing 100 mg and 500 mg Rituximab, …
Evaluating the efficacy and safety of Zytux - PubMed
Zytux™ (Rituximab, AryoGen Pharmed) used in the present study for multiple sclerosis (MS) patients is basically a biosimilar rituximab. In this observational study, a total of 100 patients …
Zytux 治疗难治性重症肌无力:一项关于利妥昔单抗生物仿制药有 …
方法:在 48 周、多中心、开放标记、前瞻性队列设置中,34 名难治性 MG 参与者被分配接受 Zytux 输注,Zytux 是一种利妥昔单抗生物仿制药,根据经过验证的方案。
- 某些结果已被删除